For anyone in Malya looking to source CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. The key implication for Malya researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the evaluation methodology is identical for researchers everywhere. Separating quality CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram showing ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. This guide guides Malya researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Malya comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Quality CJC-1295 sourcing begins with a simple filter: does this vendor publish batch-specific COAs proactively? Those who make this data freely available are signalling genuine quality commitment. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger serious immune reactions even at minute levels. For Malya researchers evaluating vendors with limited track records: a modest first purchase to test the product before committing to research quantities is standard practice in the community. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Malya
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the known safety profile is based on research literature rather than clinical trials. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution kept at 2-8°C refrigerated and consumed within 4 weeks; reconstitute only with bac water. The primary quality-related safety risk in CJC-1295 research is endotoxin from inadequately tested product — a confirmed endotoxin test result in the lot-matched COA is the key safeguard. PubMed and related preprint servers represent the most comprehensive research databases for CJC-1295 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
